Life-altering gene transfer therapies for serious disorders of the brain and central nervous system, including Parkinson’s disease, Epilepsy and Huntington’s chorea.
Recent News
Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer More
Neurologix Announces Second Quarter 2011 Financial
Results More
Results More
Neurologix Presents New Confirmatory Results for
Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee More
Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee More